697 Views
Hemophilia and Rare Bleeding Disorders
Henrik Ostergaard, PhD
Scientific Director
Hemab Therapeutics
Copenhagen, Hovedstaden, Denmark
Minka Zivkovic, MSc
Ph.D. candidate
Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
Utrecht, Utrecht, Netherlands
Prafull S. Gandhi
Scientific Director
Hemab Therapeutics
Copenhagen, Hovedstaden, Denmark
Mads Kjelgaard-Hansen
Principal Scientist
Novo Nordisk
Copenhagen, Hovedstaden, Denmark
Mie L. Broberg
Pharmacokineticist
Novo Nordisk
Copenhagen, Hovedstaden, Denmark
Torben Elm
Senior Scientist
Novo Nordisk
Copenhagen, Hovedstaden, Denmark
Mette Stougaard Kyhn
Senior Scientist
Novo Nordisk
Copenhagen, Hovedstaden, Denmark
Monika N. Løvgreen
Coordinator
Novo Nordisk
Copenhagen, Hovedstaden, Denmark
Eva H. Olsen
Director
Hemab Therapeutics
Copenhagen, Hovedstaden, Denmark
Catherine J. Rea
Medical Director
Hemab Therapeutics
41 King George Square, Richmond, England, United Kingdom
Benny Sorensen
CEO
Hemab Therapeutics
Cambridge, Massachusetts, United States
Soren E. Bjorn
Co-founder
Hemab Therapeutics
Copenhagen, Hovedstaden, Denmark
Roger E.G. Schutgens, MD, PhD, MSc
Internist-hematologist, Professor
Center for Benign Hematology, Thrombosis and Hemostasis, Van Creveldkliniek, University Medical Center Utrecht and University Utrecht, Utrecht, The Netherlands
Utrecht, Utrecht, Netherlands
Rolf T. Urbanus
Associate Professor
Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
Utrecht, Utrecht, Netherlands
Johan H. Faber
Co-founder & CTO
Hemab Therapeutics
Copenhagen, Hovedstaden, Denmark